VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

K-ras mutations promote angiogenesis in lung cancer and contribute to the drug resistance of cancer cells. It is not clear whether K-ras mutated adenocarcinomas are sensitive to anti-angiogenic therapy with monoclonal antibodies (mAbs) that target vascular endothelial growth factor (VEGF). Anti-angi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Hervé, Virginie, Rabbe, Nathalie, Guilleminault, Laurent, Paul, Flora, Schlick, Laurène, Azzopardi, Nicolas, Duruisseaux, Michael, Fouquenet, Delphine, Montharu, Jérôme, Redini, Françoise, Paintaud, Gilles, Lemarié, Etienne, Cadranel, Jacques, Wislez, Marie, Heuzé-Vourc’h, Nathalie
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2014
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623465/
https://ncbi.nlm.nih.gov/pubmed/25484066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.34454
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados